Intraprostatic PRX302 Injection to Treat Localised Prostate Cancer

Inclusion Criteria: * Life expectancy ≥ 10 years. * Serum prostate-specific antigen (PSA) ≤ 15ng/mL. * A histologically proven, clinically significant lesion visible on mpMRI (magnetic resonance imaging) that is accessible to PRX302 transperineal injection. * Radiological stage T1-T2 N0 Mx/M0 disease. * Targeted prostate biopsy within 6 months prior to dosing, with a clinically significant lesion correlating with an mpMRI visible lesion. Exclusion Criteria: * Previous radiation therapy to the pelvis. * Androgen suppression or anti-androgen therapy within the 12 months prior to dosing, for prostate cancer. * Use of 5-alpha reductase inhibitor within the 3 months prior to dosing. * Evidence of metastatic disease or nodal disease outside the prostate on bone scan or cross-sectional imaging. * Inability to tolerate transrectal ultrasound (TRUS). * Known allergy to latex or gadolinium (Gd). * Prior rectal surgery preventing insertion of the TRUS probe. * Any previous ablative procedures performed on the prostate, e.g., electroporation, radiofrequency ablation, high-intensity focused ultrasound (HIFU), cryosurgery, photochemical, thermal or microwave therapy to treat cancer of the prostate. * Unable to have pelvic MRI scanning (severe claustrophobia, permanent cardiac pacemaker, metallic implant, etc., likely to contribute significant artifact to images).